ADA 2026 5 - 8 June 2026

Serum Proteomics Suggest Novel Mechanisms of Action of Semaglutide in Reducing the Risk of MACE in the SELECT Trial

Authors :

Helen M. Colhoun¹; John E. Deanfield²; Steven E. Kahn³; A. Michael Lincoff⁴; Ildiko Lingvay⁵; Jorge Plutzky⁶; Kristian Hessellund⁷; G. Kees Hovingh⁷; Kristoffer Jensen Kolnes⁷; Peter E. Weeke⁷; Lotte Bjerre Knudsen⁸; Jan Christian Refsgaard⁷

Affiliations

View Details Hide Details

Keywords

Obesity

Cardiovascular Disease

Congress oral presentation

GLP-1 RA

Semaglutide

PHASE 3 (RCT)

Search Science Hub

Are you a healthcare professional?

Serum Proteomics Suggest Novel Mechanisms of Action of Semaglutide in Reducing the Risk of MACE in the SELECT Trial